Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study
Condition(s):BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerLast Updated:March 24, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):BRCA Wild Type Platinum Sensitive Recurrent Ovarian CancerLast Updated:March 24, 2023Recruiting
Condition(s):Epithelial Ovarian Cancer; Ovarian Cancer; Ovarian Cancer Stage III; Ovarian Cancer Stage IVLast Updated:January 26, 2022Not yet recruiting
Condition(s):Platinum-Resistant Fallopian Tube Carcinoma; Platinum-Resistant Ovarian Carcinoma; Platinum-Resistant Primary Peritoneal Carcinoma; Recurrent Fallopian Tube Carcinoma; Recurrent Ovarian Carcinoma; Recurrent Primary Peritoneal CarcinomaLast Updated:February 8, 2024Not yet recruiting
Condition(s):Ovarian Cancer by FIGO Stage; Ovarian Cancer Stage III; Ovarian Cancer Stage IVLast Updated:October 17, 2023Recruiting
Condition(s):Ovarian NeoplasmsLast Updated:July 1, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.